EBR Systems Showcases Innovation at Heart Rhythm 2026
EBR Systems, a pioneer in advanced cardiac pacing technologies, has announced its participation in the highly anticipated Heart Rhythm 2026, scheduled to take place from April 23–26, 2026, in Chicago, Illinois. The company’s presence at this global gathering of electrophysiology experts highlights its continued commitment to transforming the treatment of heart failure through cutting-edge innovation.
At the center of EBR Systems’ showcase is its groundbreaking WiSE System, the world’s only leadless left ventricular endocardial pacing (LVEP) system. Designed to improve cardiac resynchronization therapy (CRT), the WiSE System represents a significant advancement for patients who are unable to benefit from conventional pacing technologies.
Advancing Cardiac Resynchronization Therapy
Cardiac resynchronization therapy has long been a cornerstone in the management of heart failure, particularly for patients with dyssynchronous heart rhythms. However, traditional CRT methods are not suitable for all patients, leaving a critical unmet need in the field.
EBR Systems addresses this gap with the WiSE System, which enables wireless pacing of the left ventricle. Unlike conventional systems that rely on leads placed within veins, the WiSE System uses ultrasound-based energy transmission to stimulate the heart. This leadless approach reduces complications associated with leads and provides an alternative for patients who previously had limited treatment options.
The company’s participation at Heart Rhythm 2026 serves as an important platform to present real-world evidence and clinical outcomes that demonstrate the effectiveness of this innovative technology.
Scientific Sessions Highlight Real-World Data
A key highlight of EBR Systems’ presence at the conference will be its involvement in multiple scientific sessions designed to share insights and clinical experiences with the WiSE System.
One of the featured presentations, titled “Real World Experience with the WiSE System: Early Post-Approval US Practice and Outcomes,” will be delivered by Dr. Niraj Varma. Scheduled for Friday, April 24, this session will provide valuable data on early adoption and patient outcomes following the system’s approval in the United States.
The presentation is expected to shed light on how the WiSE System performs in real-world clinical settings, offering insights into patient selection, procedural success rates, and overall therapeutic benefits. Such data is critical for clinicians considering new treatment approaches for complex heart failure cases.
Expert-Led Symposium on Leadless Pacing
In addition to scientific presentations, EBR Systems will host a dedicated lunch symposium titled “Getting WiSE with Leadless LV Endocardial Pacing.” This session will bring together leading experts in electrophysiology to discuss the evolving landscape of cardiac pacing technologies.
The symposium will be moderated by Dr. Robert Canby and will feature presentations from Dr. David Slotwiner, Dr. Devi Nair, and Dr. Niraj Varma. Together, these specialists will explore the clinical advantages of leadless pacing, share patient case studies, and discuss best practices for integrating the WiSE System into routine care.
This collaborative forum underscores the growing interest in next-generation pacing solutions and the importance of knowledge exchange among healthcare professionals.
Strong Commercial Momentum in the United States
EBR Systems’ participation at Heart Rhythm 2026 comes at a pivotal moment in the company’s growth trajectory. Following U.S. regulatory approval of the WiSE System in April 2025, the company has made significant strides in commercial deployment.
The successful completion of initial commercial implants in the United States marks a major milestone, demonstrating both physician confidence and patient demand for the technology. Additionally, the company has secured key reimbursement pathways, including New Technology Add-On Payment (NTAP) and Transitional Pass-Through (TPT) status. These reimbursements play a crucial role in facilitating broader adoption by healthcare providers.
Furthermore, EBR Systems has initiated the WiSE-UP post-approval study, aimed at collecting long-term data on safety and effectiveness. This study is expected to further validate the system’s clinical value and support its integration into standard treatment protocols.
Leadership Perspective on Innovation and Impact
Commenting on the company’s participation, John McCutcheon, President and CEO of EBR Systems, emphasized the significance of this year’s conference.
He noted that the timing aligns with several key achievements, including FDA approval, early commercial success, and ongoing clinical research. According to McCutcheon, Heart Rhythm 2026 provides an ideal मंच to demonstrate how EBR Systems is redefining cardiac resynchronization therapy and improving outcomes for patients with heart failure.
His remarks reflect the company’s broader vision of leveraging innovation to address unmet medical needs and enhance patient care.
Engaging with the Global Electrophysiology Community
Beyond presentations and symposiums, EBR Systems will maintain an active presence on the exhibition floor, where attendees can explore the WiSE System firsthand. The company’s booth will serve as a hub for interaction, education, and collaboration, allowing clinicians to engage directly with experts and learn more about the technology.
Such engagement is essential in fostering adoption and building confidence among healthcare providers. By participating in both educational and experiential activities, EBR Systems aims to strengthen its relationships within the global electrophysiology community.
Regulatory and Ownership Considerations
EBR Systems also provided important information regarding its ASX-traded CHESS Depositary Interests (CDIs). These securities are issued under Regulation S of the U.S. Securities Act of 1933, which applies to offerings made outside the United States.
As a result, the CDIs are not registered under U.S. securities laws, and their resale within the United States is restricted unless certain conditions are met. Investors must comply with applicable regulations, including limitations on sales to U.S. persons and requirements for eligible exemptions.
This disclosure highlights the company’s adherence to regulatory standards while maintaining transparency with investors.
As EBR Systems continues to expand its footprint, its participation at Heart Rhythm 2026 represents more than just a conference appearance—it is a statement of progress and ambition. The company’s innovative approach to leadless pacing has the potential to reshape the standard of care for heart failure patients worldwide.
With growing clinical evidence, increasing physician adoption, and strong commercial momentum, the WiSE System is poised to play a transformative role in cardiac therapy. Events like Heart Rhythm 2026 provide a critical मंच for sharing knowledge, advancing research, and driving the future of cardiovascular medicine.
In the years ahead, EBR Systems is expected to remain at the forefront of innovation, delivering solutions that not only address current challenges but also pave the way for improved patient outcomes across the globe.
About EBR Systems
EBR Systems is a cardiac rhythm management company on a clear mission: to transform the lives of people with heart failure by helping physicians deliver optimal cardiac pacing. The WiSE System—the first FDA approved system for leadless left ventricular endocardial pacing (LVEP) in CRT—combines advanced engineering with peer-reviewed clinical evidence to expand access for patients who previously lacked options and to improve outcomes.
The WiSE System delivers LV endocardial pacing without a transvenous LV lead using targeted ultrasound. A subcutaneous transmitter and battery detect the RV pacing signal and, within milliseconds, emit ultrasound energy that a rice-sized endocardial electrode converts into an electrical pulse—enabling synchronized biventricular pacing. This LVEP approach is engineered for versatility across patient anatomies and is supported by peer-reviewed outcomes from SOLVE-CRT pivotal trial. WiSE is approved for commercial use in the United States and limited to clinical study use outside of the United States.
